Duke Collier

Duke Collier currently serves as CEO of Arsenal Medical and is a Senior Advisor with Polaris Ventures. Prior to his role at Polaris, Mr. Collier was Executive Vice President at Genzyme where he managed and built several of Genzyme’s newer businesses, including its oncology and cardiovascular business units. During his tenure at Genzyme, Mr. Collier was responsible for building the biosurgery business and oversees the company’s efforts in multiple sclerosis and other immune disorders. He has also led some of Genzyme’s significant acquisitions and the formation of MG Biotherapeutics, Genzyme’s joint venture with Medtronic Inc., which is focused on cardiac cell therapy.